Phase 11 First-In-Human study designed to assess safety, tolerability, right dose for Phase 2 and early signs of efficacy of…
Funding expected to support operations into Q1 2026. Anticipated AMPLIFY-7P Phase 2 interim analysis expected in Q3 2025. BOSTON, June…
BrainsWay is actively evaluating similar investments in other leading U.S. mental health providers to raise awareness and expand access to…
Company previously granted extension until June 30, 2025 to regain compliance with Nasdaq’s Equity Rule requirementNEWTOWN, Pa., June 04, 2025…
TORONTO, June 04, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a…
Partnership to provide demand generation, thought leadership, and media services BALTIMORE, June 3, 2025 /PRNewswire/ -- Sage Growth Partners (SGP), a healthcare growth…
Company enters option agreement with JiKang Therapeutics to in-license novel APJ agonist antibody New composition of matter IP filed for…
EDEN PRAIRIE, Minn., June 03, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a…
Company to Expand Patented Wellness Approach into High-Growth Cognitive and Restorative Sleep Markets, Emphasizing Scientific Rigor and Unique Formulations SCOTTSDALE,…
BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Rose Hill Life Sciences, a global leader in the research and intellectual property…